Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
TRIB(NASDAQ:TRIB) DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”).
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
TRIBDUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director.
Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
TRIBApproval Facilitates Immediate Offshored and Outsourced Manufacturing
Trinity Biotech Q4 EPADS $(0.1279) Beats $(0.28) Estimate, Sales $15.86M Miss $16.00M Estimate
TRIBTrinity Biotech Receives Non-Compliance Notice From Nasdaq Global Select Regarding Requirement For Minimum Market Value Of Publicly Held Shares And Nasdaq Minimum Bid Price Requirement
TRIBTrinity Biotech Announces Additional $4M Funding
TRIBTrinity Biotech Amends Credit Agreement With Perceptive Advisors To Boost Liquidity And Support Transformation Plan; Secures $5.5M In Additional Funding, Extends $5M Payment To 2025, And Issues 1.5M New Warrants At $0.80 Exercise Price
TRIBTrinity Biotech Reiterates Guidance To Achieve 2024 Sales Revenue For TrinScreen HIV Of Approximately $10M
TRIBTrinity Biotech Reiterates Guidance To Achieve $20M Of Annualized Run-rate EBITDASO On Annualized Run-rate Revenues Of $75M By Q2 2025
TRIBTrinity Biotech Q3 2024 GAAP EPADS $(0.46) Beats $(0.54) Estimate, Sales $15.15M Miss $16.50M Estimate
TRIBInsights Ahead: Trinity Biotech's Quarterly Earnings
TRIBTrinity Biotech Announces Strategic Collaboration With PulseAI To Enhance Continuous Glucose Monitor Biosensor Technology
TRIB